Device-based Rate Versus Rhythm Control in Symptomatic Recent-onset Atrial Fibrillation (RACE 9 OBSERVE-AF)

No registrations found.

Ethical review Positive opinion **Status** Recruiting

Health condition type -

Study type Interventional

Summary

ID

NL-OMON22526

Source

NTR

Brief title

RACE 9 Observe-AF

Health condition

Atrial fibrillation

Sponsors and support

Primary sponsor: MUMC+

Source(s) of monetary or material Support: ZonMW, NWO, Hartstichting

Intervention

Outcome measures

Primary outcome

Presence of sinus rhythm on ECG after 4 weeks

Secondary outcome

Implementation of the telemonitoring infrastructure, MACCE, AF recurrences/progression, cost-effectiveness, quality of life, patient reported outcome measures

Study description

Background summary

Continuous heart rhythm monitoring elucidated the recurrent and transient nature of recentonset atrial fibrillation (AF). The RACE7 ACWAS showed that a wait-and-see approach (WAS)
in patients with recent-onset AF (rate control for symptom relief followed by delayed
cardioversion if needed <48h) allows spontaneous conversion to sinus rhythm in 69% of
patients, obviating active cardioversion. Recurrences within one month were seen in 30% of
patients in both groups, i.e. the initially chosen strategy did not affect the recurrence pattern.
Considering the latter, it remains unclear whether cardioversion is needed at all, especially
since cardioversion strategy does not seem to affect behaviour of the arrhythmia over time.
Instead of cardioversion a watchful-waiting rate control strategy may be appropriate as initial
strategy. This allows observing the electrical and clinical behavior of arrhythmia, providing a
solid basis for comprehensive and effective early rhythm control. This study is a multi-center
clinical randomized controlled trial to show non-inferiority of watchful-waiting with rate
control versus routine care in terms of prevalence of sinus rhythm at 4 weeks follow-up, using
a novel telemonitoring infrastructure to guide rate and rhythm control during follow-up.

Study objective

The watchful waiting strategy is non-inferior compared to routine care in terms of effectiveness (presence of sinus rhythm on ECG after 4 weeks) in patients with recent-onset, symptomatic atrial fibrillation.

Study design

Patients will have a follow-up visit after 4 weeks. Total follow-up duration will be one year.

Intervention

watchful waiting

Contacts

Public

Maastricht UMC+ Rachel van der Velden 043-3876885 **Scientific**

Maastricht UMC+ Rachel van der Velden

043-3876885

Eligibility criteria

Inclusion criteria

Age > 18 years, ECG with atrial fibrillation, duration current episode <36 hours, symptoms due to AF, able and willing to sign informed consent, able and willing to use telemonitoring infrastructure

Exclusion criteria

History of persistent AF, signs of myocardial infarction, signs of acute heart failure, hemodynamic instability, history of (untreated) sick sinus syndrome or Wolff-Parkinson-White syndrome, history of (unexplained) syncope, deemed unsuitable by attending physician, currently enrolled in another clinical trial

Study design

Design

Study type: Interventional

Intervention model: Parallel

Allocation: Randomized controlled trial

Masking: Open (masking not used)

Control: Active

Recruitment

NL

Recruitment status: Recruiting
Start date (anticipated): 16-11-2020

Enrollment: 490

Type: Anticipated

IPD sharing statement

Plan to share IPD: Yes

Plan description

All elements from the CRF matching a future project's CRF may be provided for an

aggregated analysis

Ethics review

Positive opinion

Date: 16-04-2021

Application type: First submission

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID

NTR-new NL9416

Other METC UM/aZM: METC 20-017

Study results

Summary results

_